0001209191-22-040279.txt : 20220701
0001209191-22-040279.hdr.sgml : 20220701
20220701164508
ACCESSION NUMBER: 0001209191-22-040279
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220701
FILED AS OF DATE: 20220701
DATE AS OF CHANGE: 20220701
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aggarwal Gaurav
CENTRAL INDEX KEY: 0001551965
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37490
FILM NUMBER: 221062056
MAIL ADDRESS:
STREET 1: C/O PANORAMA CAPITAL
STREET 2: 2440 SAND HILL ROAD, SUITE 302
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sierra Oncology, Inc.
CENTRAL INDEX KEY: 0001290149
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
BUSINESS PHONE: (605) 376-8679
MAIL ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: ProNAi Therapeutics Inc
DATE OF NAME CHANGE: 20040513
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-01
1
0001290149
Sierra Oncology, Inc.
SRRA
0001551965
Aggarwal Gaurav
C/O SIERRA ONCOLOGY, INC.
1820 GATEWAY DR., SUITE 110
SAN MATEO
CA
94404
1
0
0
0
Common Stock
2022-07-01
4
D
0
2735853
55.00
D
0
I
By: Vivo Opportunity Fund Holdings, L.P.
Stock Option (right to buy)
13.87
2022-07-01
4
D
0
1500
0.00
D
2029-11-29
Common Stock
1500
0
D
Stock Option (right to buy)
13.98
2022-07-01
4
D
0
6874
0.00
D
2030-06-09
Common Stock
6874
0
D
Stock Option (right to buy)
18.11
2022-07-01
4
D
0
6000
0.00
D
2031-06-08
Common Stock
6000
0
D
Series A Warrant
13.20
2022-07-01
4
D
0
1455384
0.00
D
2019-11-13
2024-11-13
Common Stock
1455384
0
I
By: Vivo Opportunity Fund Holdings, L.P.
Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc ("GSK"), Orikum Acquisition Inc. ("Merger Sub") and the Issuer (the "Merger Agreement"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the "Merger"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest.
Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
The option fully vested on November 29, 2020.
At the effective time of the Merger, each stock option outstanding, whether vested or unvested, automatically and without any required action on the part of the Reporting Person, was cancelled in exchange for the right to receive an amount in cash equal to the excess, if any, of $55.00 over the per share exercise price of such stock option.
The option fully vested on June 9, 2021.
The option fully vested on June 8, 2022.
Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the "Series A Warrants") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants.
/s/ Gaurav Aggarwal; By: Mary Christina Thomson, Attorney-In-Fact
2022-07-01